MedTrace Logo

Application of the sG8 Scale in Real-World Geriatric Oncology Patients

NCT06939764 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 346

Last updated 2025-04-23

No results posted yet for this study

Summary

This study is a multicenter, prospective, observational study. The study included patients aged 65 and older with solid tumors requiring systemic anti-tumor therapy. All patients underwent screening using the sG8 scale before the start of treatment, followed by routine treatment based on a plan developed through clinician decision-making. The study did not intervene in any way with the patients' diagnosis and treatment, and relevant clinical data during the treatment process were recorded accurately for follow-up patients. Study data were obtained from the electronic medical record databases and hospital information systems of multiple centers, including Sichuan Cancer Hospital. Patient clinicopathological features, pathological diagnoses, clinical stages, previous treatment histories, as well as anti-tumor treatment regimens after patient enrollment, drug dosages per cycle, treatment start times, incidence and grades of adverse events (AEs), and tumor response were extracted and collected from the medical records. All data were entered, managed, quality-controlled, exported, and analyzed through a real-world data management platform (RWDMP).

Conditions

  • Solid Cancers
  • Geriatric Assessment

Interventions

OTHER

Geriatric Screening using the sG8 scale

Geriatric screening using the sG8 scale

Sponsors & Collaborators

  • Sichuan Cancer Hospital and Research Institute

    lead OTHER

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-16
Primary Completion
2025-12-25
Completion
2026-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06939764 on ClinicalTrials.gov